11/11/2024  17:01:11 Var. - Volume Denaro11:35:10 Lettera12:23:05 Capitalizzazione di mercato Dividend Y. Rapporto P/E
141.78EUR - 250
Fatturato: 35,420.84
138.08Quantità in denaro: 73 139.36Quantità in lettera: 72 22.04 bill.EUR - -

Descrizione business

Illumina is improving human health by unlocking the power of the genome. The company's focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Illumina's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Jacob Thaysen, PhD
Consiglio di amministrazione
Ankur Dhingra, Steve Barnard, PhD, Nicole Berry, Todd Christian, Everett Cunningham, Scott Davies, Pat Leckman, Kevin Pegels, Carissa Rollins, Salli Schwartz, Bas Verhoef, Jakob Wedel, Gretchen Weightman, Jenny Zheng
Consiglio di sorveglianza
Stephen P. MacMillan, Jacob Thaysen, PhD, Frances Arnold, PhD, Caroline Dorsa, Robert S. Epstein, Scott Gottlieb, Gary S. Guthart, Anna Richo, Philip Schiller, Sue Siegel, Scott B. Ullem
 

Dati aziendali

Name: Illumina Inc.
Indirizzo: 5200 Illumina Way,San Diego, California 92122, USA
Telefono: +1-858-202-4500
Fax: +1-858-202-4766
E-mail: info@illumina.com
Internet: www.illumina.com/
Industria: Healthcare
Settore: Medical Products
Sub settore: Advanced Medical Devices
Fine dell'anno finanziario: 31/12
Flottante libero: 48.29%
Data dell'IPO: 28/07/2000

Rapporti con gli investitori

Name: -
IR telefono: +1-858-291-6421
IR Fax: -
IR e-mail: ir@illumina.com

Principali azionisti

Altri
 
56.21%
Vanguard Group
 
11.41%
BlackRock Inc.
 
8.35%
EDGEWOOD MANAGEMENT LLC
 
4.32%
State Street Corporation
 
4.22%
BAILLIE GIFFORD CO
 
3.31%
LOOMIS SAYLES CO L P
 
2.78%
HENDERSON GROUP PLC
 
2.76%
Morgan Stanley
 
2.32%
Altri
 
4.31%